KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

AbCellera Biologics (ABCL) Other Non Operating Income (2020 - 2023)

AbCellera Biologics' Other Non Operating Income history spans 4 years, with the latest figure at $10.5 million for Q4 2023.

  • For the quarter ending Q4 2023, Other Non Operating Income rose 377.45% year-over-year to $10.5 million, compared with a TTM value of $14.7 million through Dec 2023, up 579.69%, and an annual FY2024 reading of $13.6 million, down 3.78% over the prior year.
  • Other Non Operating Income for Q4 2023 was $10.5 million at AbCellera Biologics, up from $2.8 million in the prior quarter.
  • The five-year high for Other Non Operating Income was $11.9 million in Q4 2020, with the low at -$18.3 million in Q4 2021.
  • Average Other Non Operating Income over 4 years is $1.1 million, with a median of $2.2 million recorded in 2022.
  • Biggest YoY gain for Other Non Operating Income was 1685.67% in 2021; the steepest drop was 253.7% in 2021.
  • Tracing ABCL's Other Non Operating Income over 4 years: stood at $11.9 million in 2020, then plummeted by 253.7% to -$18.3 million in 2021, then skyrocketed by 79.3% to -$3.8 million in 2022, then skyrocketed by 377.45% to $10.5 million in 2023.
  • Per Business Quant, the three most recent readings for ABCL's Other Non Operating Income are $10.5 million (Q4 2023), $2.8 million (Q3 2023), and -$2.0 million (Q2 2023).